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(E)-Methyl/ethyl-3-(2-hydroxyphenyl)acrylates 3a-x have been prepared by the reaction of salicylaldehydes 1a-l with 
Wittig reagents such as methyl (triphenylphosphoranylidene)acetate 2a and ethyl (triphenylphosphoranylidene)acetate 2b in 
dry DCM at room temperature. All the synthesized compounds have been evaluated for free-radical scavenging and α-
glucosidase inhibitory activities. Compounds 3c and 3d display DPPH free radical scavenging activity. All the compounds 
have shown ABTS free radical scavenging activity except four compounds 3s-t and 3w-x. Compounds 3g, 3p and 3r display 
α-glucosidase inhibitory activity. 
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(E)-α,β-Unsaturated esters1 are an important 
compounds and valuable intermediates for the 
preparation of various synthetic and natural products2. 
The widely used methods for the preparation of these 
esters are the Wittig reaction3 and Horner-
Wadsworth-Emmons using alkoxycarbonyl 
methylene(triphenyl)phosphoranes and trialkyl 
phosphonoacetates3-10. These esters have applications 
in the food, polymer and perfume industries. 
Therefore, the commercial scale preparations of these 
compounds are necessary. 
As part of our ongoing research on the preparation 
of heterocyclic compounds11,12 and natural 
products13,14, recently, we have prepared various novel 
heterocyclic compounds by the reaction of 
salicylaldehydes with β-ketoesters15-18. The reaction 
of salicylaldehydes with Wittig reagent provides the 
(E)-α,β-unsaturated esters and its biological properties 
have not been studied. Therefore, the present 
manuscript describes the preparation of α,β-
unsaturated esters and their evaluation of DPPH, 
ABTS.+ free radical scavenging and α-glucosidase 
inhibitory activities. 
Results and Discussion 
The target (E)-methyl/ethyl 3-(2-
hydroxyphenyl)acrylate compounds 3a-x have been 
prepared by the reaction of salicylaldehydes 1a-l  
with Wittig reagents19 namely methyl 
(triphenylphosphoranylidene)acetate 2a and ethyl 
(triphenylphosphoranylidene)acetate 2b in dry DCM 
at RT (Scheme I, Table I). All the compounds are 
characterized by spectral data. 
Biology 
The prepared compounds 3a-x have been evaluated 
for their biological activities such as DPPH, ABTS.+ 
free radical scavenging and α-glucosidase  
inhibitory20 for the first time and the results are 
described below. 
Free radicals scavenging activity 
The DPPH and ABTS.+ free radical scavenging 
activity of compounds 3a-x are presented in Table II 
along with the standard drugs Ascorbic acid and 
Trolox (SC50 values)
20. Among the prepared 
compounds, the methoxy (5th position) substituted 
compounds 3c (SC50 6.47 μg/mL) and 3d (SC50 6.21 
μg/mL) have shown the DPPH free radical 
scavenging activity in comparison with the standard 
compound Ascorbic acid (SC50 4.08 μg/mL). 
However, the methoxy compounds 3e-f positioned at 
4th position and remaining compounds 3a-b and 3g-x 
could not display the activity. 




The ABTS.+ free radical scavenging activity of 
compounds 3a-r and 3u-v have shown ranging from 
SC50 1.24-3.93 μg/mL when compared to standard 
compound Trolox (SC50 1.16 μg/mL). It is interesting 
to note that twenty compounds (methyl, methoxy, 
halo substitution) have shown ABTS.+ free radical 
scavenging activity among the prepared 24 
compounds. The nitro substituted compounds 3s-t and 
di nitro substituted compounds 3w-x could not shown 
ABTS.+ free radical scavenging activity. 
 
α-Glucosidase inhibitory activity 
α-Glucosidase inhibitory activity of compounds 3a-
x and their IC50 values presented in Table II along with 
the standard drug Acarbose20. Three compounds have 
shown α-glucosidase inhibitory activity in the present 
series of compounds. The methyl substituted 
compound 3g (IC50 4.39 µg/mL) has shown better α-
glucosidase inhibitory activity when compared to 
methoxy 3c-f, and halo 3i-o. Interestingly, the dichloro 
3p (IC50 10.79 µg/mL) shown moderate activity and 
dibromo compound 3r (IC50 2.31 µg/mL) displayed 
potent α-glucosidase inhibitory activity (Table II). 
 
Experimental Section 
All the chemicals and reagents were purchased 
from Aldrich (Sigma-Aldrich, USA), AVRA 
Chemicals Pvt. Ltd (Hyderabad, India) and were used 
without further purification. Reactions were 
monitored by thin layer chromatography (TLC) on 
pre-coated silica gel 60 F254 (mesh); spots were 
visualized under UV light. Melting points were 
determined on a Stuart melting point apparatus and 
are uncorrected. IR spectrum was recorded with a 
Thermo Nicolet Nexus 670 FT spectrometer. 1H and 
13C NMR spectra were recorded on Bruker Avance 
300, 400 and 500 MHz spectrometers. Chemical shifts 
(δ) are quoted in parts per million and are referenced 
to tetramethylsilane (TMS) as internal standard. ESI-
MS were obtained on quarto micro spectrometer. 
 
General experimental procedure for the 
preparation of compounds, 3a-x 
Methyl (triphenylphosphoranylidene)acetate 2a 
(1.0 mmol) was added to a stirred solution of salicyl 
aldehyde 1a (1.0 mmol) in dry DCM (2 mL) at RT. 
The reaction mixture was stirred at the same 
temperature until the starting materials disappeared 
(TLC). After completion of the reaction, the solvent 
was removed and the reaction mixture was purified by 
column chromatography (EtOAc/hexane) to give 
colourless solid 3a. Similarly, the compounds 3b-x 
have been prepared by the reaction of 
salicylaldehydes 1a-l with Wittig reagents such as 
methyl (triphenylphosphoranylidene)acetate 2a and 
 
Table I — Preparation of (E)-methyl/ethyl-3-(2-hydroxyphenyl) 
acrylates 3a-x 
Entry Compd R R1 R2 R3 Yield a (%) 
1 3a H H H CH3 84 
2 3b H H H C2H5 86 
3 3c OCH3 H H CH3 82 
4 3d OCH3 H H C2H5 84 
5 3e H OCH3 H CH3 82 
6 3f H OCH3 H C2H5 82 
7 3g CH3 H H CH3 76 
8 3h CH3 H H C2H5 80 
9 3i F H H CH3 70 
10 3j F H H C2H5 72 
11 3k Cl H H CH3 74 
12 3l Cl H H C2H5 75 
13 3m Br H H CH3 77 
14 3n Br H H C2H5 79 
15 3o Cl H Cl CH3 74 
16 3p Cl H Cl C2H5 74 
17 3q Br H Br CH3 68 
18 3r Br H Br C2H5 70 
19 3s NO2 H H CH3 62 
20 3t NO2 H H C2H5 65 
21 3u NO2 H Br CH3 56 
22 3v NO2 H Br C2H5 54 
23 3w NO2 H NO2 CH3 48 
24 3x NO2 H NO2. C2H5 42 











ethyl (triphenylphosphoranylidene)acetate 2b under 
our optimized conditions. All the compounds are 
characterized by spectral data. 
Methyl(E)-3-(2-hydroxyphynyl)arylate, 3a: 
Colourless solid. m.p.136-137°C. 1H NMR (500 
MHz, CDCl3): δ 
1H NMR 8.06 (d, J = 16.2 Hz, 1H, 
CH), 7.47 (dd, J = 7.7, 1.2 Hz, 1H, aromatic), 7.27-
7.21 (m, 1H, aromatic), 6.92 (t, J = 7.5 Hz, 1H, 
aromatic), 6.86 (dd, J = 8.1, 0.7 Hz, 1H, aromatic), 
6.72 (s, 1H, OH), 6.65 (d, J = 16.2 Hz, 1H, CH), 3.83 
(s, 3H, OCH3); ESI-MS: m/z [M+H]
+ 179. 
Ethyl(E)-3-(2-hydroxyphynyl)acrylate, 3b: 
Colourless solid. m.p.143-144°C. 1H NMR (400 
MHz, CDCl3): δ 8.08 (d, J = 16.1 Hz, 1H, CH), 7.45 
(s, 2H, aromatic), 7.22 (t, J = 7.2 Hz, 1H, aromatic ), 
6.89 (d, J = 6.9 Hz, 2H, aromatic, OH), 6.67 (d, J = 
16.1 Hz, 1H, CH), 4.30 (d, J = 6.9 Hz, 2H, OCH2), 
1.33 (dd, J = 24.8, 18.2 Hz, 3H, OCH3);
 ESI-MS: m/z 
[M+H]+ 193. 
Methyl(E)-3-(2-hydroxy-5-methoxyphenyl)-
acrylate, 3c: Colourless solid. m.p.126-130°C. 
1H NMR (400 MHz, CDCl3): δ 8.03 (d, J = 16.2 Hz, 
1H, CH), 6.97 (d, J = 2.6 Hz, 1H, aromatic), 6.86-
6.77 (m, 2H, aromatic), 6.62 (s, 1H, OH), 6.58 (d, J = 
16.1 Hz, 1H, CH), 3.83 (d, J = 5.4 Hz, 3H, OCH3), 
3.77 (s, 3H, OCH3); ESI-MS: m/z [M+H]
+ 209. 
Ethyl(E)-3-(2-hydroxy-5-methoxyphenyl)-
acrylate, 3d: Colourless solid. m.p.129-134°C. 
1H NMR (400 MHz, CDCl3): δ 8.02 (d, J = 16.1 Hz, 
1H, CH), 6.98 (d, J = 2.8 Hz, 1H, aromatic), 6.82 (m, 
2H, aromatic), 6.57 (d, J = 16.1 Hz, 1H, aromatic), 
6.31 (s, 1H, OH), 4.35-4.24 (m, 2H, OCH2), 3.83-3.73 
(m, 3H, OCH3), 1.40-1.31 (m, 3H, OCH3); ESI-MS: 
m/z [M+H]+ 223. 
Methyl(E)-3-(2-hydroxy-4-methoxyphenyl)-
acrylate, 3e: Colourless solid. m.p.126-128°C. 
1H NMR (400 MHz, CDCl3): δ 7.98 (d, J = 16.1 Hz, 
1H, CH), 7.39 (d, J = 8.7 Hz, 1H, aromatic), 7.04 (s, 
1H, OH), 6.52 (d, J = 16.1 Hz, 1H, CH), 6.49 (dd, J = 
8.7, 2.4 Hz, 1H, aromatic), 6.41 (d, J = 2.4 Hz, 1H, 
aromatic), 3.83 (s, 3H, OCH3), 3.80 (s, 3H, OCH3); 
ESI-MASS: m/z [M+H]+ 209. 
Ethyl(E)-3-(2-hydroxy-4-methoxyphenyl)-
acrylate, 3f: Colourless solid. m.p.129-134°C. 
1H NMR (500 MHz, CDCl3): δ 8.00 (d, J = 16.1 Hz, 
1H, CH), 7.39 (d, J = 8.7 Hz, 1H, aromatic), 7.32 (s, 
1H, OH), 6.54 (d, J = 16.1 Hz, 1H, CH), 6.48 (dd, J = 
8.6, 2.3 Hz, 1H, aromatic), 6.42 (d, J = 2.4 Hz, 1H, 
 
Table II — DPPH, ABTS.+, α-glucosidase inhibitory activity profile of compounds 3a-x 
Compd DPPH % Inhibition 
25µg/mL (SC50 µg /mL) 
ABTS.+ % Inhibition 
20 µg /mL (SC50 µg /mL) 
AGI % Inhibition 
20 µg/mL (IC50 µg /mL) 
3a 12.00±0.07 98.19±0.32 (1.25) 25.79±0.62 
3b 10.42±0.22 96.71±0.48 (1.34) 35.12±0.61 
3c 72.75±0.04 (6.47) 96.37±0.64 (1.36) ND 
3d 73.17±1.23 (6.21) 98.19±0.00 (1.25) 19.72±0.00 
3e 40.41±0.86 97.28±0.00 (1.41) 19.01±0.00  
3f 42.07±0.07 97.28±0.00 (1.31) 19.01±0.00 
3g 26.56±1.49 98.64±0.00 (1.24) 80.19±1.87(4.39) 
3h 26.48±0.26 96.37±1.28 (1.36) 32.31±0.87 
3i 14.43±0.45 97.51±0.96 (1.37) 34.33±2.49 
3j 12.08±0.93 97.96±0.00 (1.29) 29.58±0.75 
3k 6.86±0.04 97.28±0.00 (1.31) 38.38±0.50 
3l 6.30±0.45 97.51±0.64 (1.37) 40.41±0.12 
3m 5.20±0.75 97.51±0.00 (1.37) 42.96±0.00 
3n 4.35±0.30 97.51±0.32 (1.37) 34.15±0.25 
3o 2.27±1.21 98.19±0.00 (1.25) 57.31±1.62 
3p 3.38±0.48 98.41±0.00 (1.38) 64.96±0.00 (10.79) 
3q ND 71.32±1.12 (3.93) 52.90±1.89 
3r 3.35±0.37 96.71±0.16 (1.34) 97.36±0.24 (2.31) 
 3s ND  5.22±1.28 53.70±0.25 
3t ND 3.29±0.16 ND 
3u 8.52±1.72 98.64±0.00 (1.24) 28.61±0.37 
3v 8.47±1.198 98.53±0.16 (1.26) 38.91±0.00 
3w ND 6.24 ±0.16 37.68±0.00 
3x ND 2.72±0.00 ND 
Ascorbic acid 85.68±0.86 (4.08) − − 
Trolox − 98.87±0.00 (1.16) − 
Acarbose − − 98.57±0.05 (2.17) 
 




aromatic), 4.33-4.24 (m, 2H, OCH2), 3.79 (s, 3H, 
OCH3), 1.39-1.29 (m, 3H, OCH3); ESI-MS: m/z 
[M+H]+ 223. 
Methyl(E)-3-(2-hydroxy-5-methylphenyl)-
acrylate, 3g: Colourless solid. m.p.136-144°C. 
1H NMR (400 MHz, CDCl3): δ 8.01 (d, J = 16.2 Hz, 
1H, CH), 7.04 (dd, J = 8.2, 1.7 Hz, 1H, aromatic), 
6.75 (d, J = 8.2 Hz, 1H, aromatic), 6.61 (d, J = 16.2 
Hz, 1H, CH), 6.38 (s, 1H, OH), 3.88-3.77 (m, 3H, 
OCH3), 2.27 (s, 3H, CH3); ESI-MS: m/z [M+H]
+ 193. 
Ethyl(E)-3-(2-hydroxy-5-methylphenyl)-
acrylate, 3h: Colourless solid. m.p.132-134°C. 
1H NMR (500 MHz, CDCl3): δ 7.97 (d, J = 16.1 Hz, 
1H, CH), 7.26 (s, 1H, aromatic), 7.03 (dd, J = 8.2, 1.7 
Hz, 1H, aromatic), 6.75 (t, J = 6.1 Hz, 1H), 6.59 (dd, 
J = 16.1, 5.4 Hz, 1H, CH), 6.24 (s, 1H, OH), 4.32-
4.24 (m, 2H, OCH2), 2.27 (s, 3H, CH3), 1.34 (t, J = 
7.1 Hz, 3H, OCH3); ESI-MS: m/z [M+H]
+ 207. 
Methyl(E)-3-(5-fluoro-2-hydroxyphenyl)-
acrylate, 3i: Colourless solid. m.p.126-128°C. 
1H NMR (500 MHz, CDCl3): δ 7.97 (d, J = 16.2 Hz, 
1H, CH), 7.16 (dd, J = 9.1, 3.0 Hz, 1H, aromatic), 
6.95 (m, Hz, 1H, aromatic), 6.80 (dd, J = 8.9, 4.5 Hz, 
1H, aromatic), 6.56 (d, J = 16.2 Hz, 1H, CH), 6.22 (d, 
J = 23.5 Hz, 1H, OH), 3.83 (d, J = 3.4 Hz, 3H, CH3). 
ESI-MS: m/z [M+H]+ 197. 
Ethyl(E)-3-(5-fluoro-2-hydroxyphenyl)acrylate, 
3j: Colourless solid. m.p.125-126°C. 1H NMR (400 
MHz, CDCl3): δ 8.02 (d, J = 16.2 Hz, 1H, CH), 7.16 
(dd, J = 9.2, 3.0 Hz, 1H, aromatic), 6.95 (ddd, J = 8.8, 
7.8, 3.0 Hz, 1H, aromatic), 6.85-6.78 (m, 1H, 
aromatic), 6.59-6.54 (d, J = 16.2 Hz, 1H, CH), 4.29 
(q, J = 7.1 Hz, 2H, OCH2), 1.39-1.32 (m, 3H, OCH3); 
ESI-MS: m/z [M+H]+ 211. 
 
Methyl(E)-3-(5-chloro-2-hydroxyphenyl)-
acrylate, 3k: Colourless solid. m.p.134-136°C. 
1H NMR (400 MHz, CDCl3): δ 7.92 (d, J = 16.2 Hz, 
1H, CH), 7.44 (d, J = 2.5 Hz, 1H, aromatic), 7.19 (dd, 
J = 8.6, 2.5 Hz, 1H,aromatic), 6.79 (d, J = 8.6 Hz, 1H, 
aromatic), 6.58 (d, J = 16.2 Hz, 1H, CH), 6.30 (s, 1H, 
OH), 3.83 (s, 3H, OCH3); ESI-MS: m/z [M+H]
+ 213. 
Ethyl(E)-3-(5-chloro-2-hydroxyphenyl)acrylate, 
3l: Colour lees solid. m.p.124-126°C. 1H NMR (400 
MHz, CDCl3): δ 8.00 (d, J = 16.2 Hz, 1H, CH), 7.72 
(s, 1H, OH), 7.42 (d, J = 2.5 Hz, 1H, aromatic), 7.17 
(dd, J = 8.6, 2.5 Hz, 1H, aromatic), 6.83 (d, J = 8.6 
Hz, 1H, aromatic), 6.64 (d, J = 16.2 Hz, 1H, CH), 
4.30 (q, J = 7.1 Hz, 2H, OCH2), 1.36 (t, J = 7.1 Hz, 
3H, OCH3); ESI-MS: m/z [M+H]
+ 227. 
Methyl(E)-3-(5-bromo-2-hydroxyphenyl)-
acrylate, 3m: Colourless solid. m.p. 135-137°C. 
1H NMR (400 MHz, CDCl3): δ 7.93 (d, J = 16.2 Hz, 
1H, CH), 7.58 (d, J = 2.3 Hz, 1H, aromatic), 7.32 (dd, 
J = 8.6, 2.4 Hz, 1H, aromatic, aromatic), 6.75 (d, J = 
8.6 Hz, 1H, aromatic), 6.72 (s, 1H, OH), 6.59 (d, J = 
16.2 Hz, 1H, CH), 3.83 (s, 3H, OCH3); ESI-MS: m/z 
[M+H]+ 257. 
Ethyl(E)-3-(5-bromo-2-hydroxyphenyl)-
acrylate, 3n: Colourless solid. m.p.138-140°C. 
1H NMR (400 MHz, CDCl3): 7.97 (d, J = 16.2 Hz, 
1H, CH), 7.57 (d, J = 2.4 Hz, 1H, aromatic), 7.51 (s, 
1H, OH), 7.36-7.27 (m, 1H, aromatic), 6.78 (d, J = 
8.6 Hz, 1H, aromatic), 6.63 (d, J = 16.2 Hz, 1H, CH), 
4.37-4.25 (m, 2H, OCH2), 1.41-1.30 (m, 3H, OCH3); 
ESI-MS: m/z [M+H]+ 271. 
Methyl(E)-3-(3,5-dichloro-2-hydroxyphenyl)-
acrylate, 3o: Colourless solid. m.p.128-130°C. 
1H NMR (400 MHz, CDCl3: δ 7.86 (d, J = 16.2 Hz, 
1H, CH), 7.37 (dd, J = 11.6, 2.4 Hz, 2H, aromatic, 
CH), 6.57 (d, J = 16.2 Hz, 1H, CH), 6.08 (s, 1H, OH), 
3.82 (s, 3H, OCH3); ESI-MS: m/z [M+H]
+ 247. 
Ethyl(E)-3-(3,5-dichloro-2-hydroxyphenyl)-
acrylate, 3p: Colourless solid. m.p.119-120°C. 
1H NMR (500 MHz, CDCl3): δ 7.85 (d, J = 16.2 Hz, 
1H, CH), 7.37 (dd, J = 18.8, 2.4 Hz, 2H, aromatic, 
CH), 6.57 (d, J = 16.2 Hz, 1H, CH), 6.04 (s, 1H, OH), 
4.30-4.25 (m, 2H, OCH2), 1.37-1.32 (m, 3H, OCH3); 
ESI-MS: m/z [M+H]+ 261. 
Methyl(E)-3-(3,5-dibromo-2-hydroxyphenyl)-
acrylate, 3q: Colourless solid. m.p.122-124°C. 
1H NMR (500 MHz, CDCl3): δ 7.84 (d, J = 16.2 Hz, 
1H, CH), 7.61 (d, J = 2.3 Hz, 1H, aromatic), 7.55 (d, J 
= 2.3 Hz, 1H, aromatic), 6.56 (d, J = 16.1 Hz, 1H, 
CH), 5.97 (s, 1H, OH), 3.81 (s, 3H, OCH3). ESI-MS: 
m/z [M+H]+ 335. 
Ethyl(E)-3-(3,5-dibromo-2-hydroxyphenyl)-
acrylate, 3r: Colourless solid. m.p. 125-127°C. 
1H NMR (500 MHz, CDCl3): δ 7.84 (d, J = 16.2 Hz, 
1H, CH), 7.60 (d, J = 2.3 Hz, 1H, aromatic), 7.56 (d, J 
= 2.3 Hz, 1H, aromatic), 6.55 (d, J = 16.1 Hz, 1H, 
CH), 6.04 (s, 1H, OH), 4.27 (q, J = 7.1 Hz, 2H, 
OCH2), 1.34 (dd, J = 9.2, 5.0 Hz, 3H, OCH3); 
13C NMR (126 MHz, CDCl3): δ 166.75, 150.34, 
137.75, 135.05, 130.75, 124.33, 121.33, 112.68, 
112.00, 60.73, 14.26; ESI-MS: m/z [M+H]+ 249. 
Methyl(E)-3-(2-hydroxy-5-nitrophenyl)acrylate, 
3s: Colourless solid. m.p. 131-133°C. 1H NMR (500 
MHz, CDCl3): δ 8.41 (d, J = 2.7 Hz, 1H, aromatic), 
8.15 (dd, J = 8.9, 2.7 Hz, 1H, aromatic), 7.95 (d, J = 




16.1 Hz, 1H, CH), 6.94 (d, J = 8.9 Hz, 1H, aromatic), 
6.70 (d, J = 16.2 Hz, 1H, CH), 3.85 (s, 3H, OCH3); 
ESI-MS: m/z [M+H]+ 224. 
Ethyl (E)-3-(2-hydroxy-5-nitrophenyl)acrylate, 
3t: Colourless solid. m.p.140-143°C. 1H NMR (400 
MHz, CDCl3): 8.93 (s, 1H, OH), 8.42 (d, J = 2.7 Hz, 
1H, aromatic), 8.15 (dd, J = 8.9, 2.7 Hz, 1H, 
aromatic), 8.05 (d, J = 16.3 Hz, 1H, CH), 7.00 (d, J = 
9.0 Hz, 1H, aromatic), 6.81 (d, J = 16.3 Hz, 1H, CH), 
4.35 (q, J = 7.1 Hz, 2H, OCH2), 1.40 (t, J = 7.1 Hz, 
3H, CH3); ESI-MS: m/z [M+H]
+ 238. 
Methyl (E)-3-(3-bromo-2-hydroxy-5-
nitrophenyl)acrylate, 3u: Colourless solid. m.p.140-
142°C. 1H NMR (500 MHz, CDCl3): δ 8.41 (d, J = 
23.6 Hz, 1H, aromatic), 8.00 (dd, J = 80.4, 69.0 Hz, 
1H, aromatic), 6.68 (d, J = 16.0 Hz, 1H, CH), 4.43 (d, 
J = 16.0 Hz, 1H, CH), 3.81 (s, 3H, OCH3); ESI-MS: 
m/z [M+H]+ 302. 
Ethyl (E)-3-(3-bromo-2-hydroxy-5-
nitrophenyl)acrylate, 3v: Colourless solid. m.p.149-
151°C. 1H NMR (500 MHz, CDCl3): δ 8.41 (d, J = 
18.6 Hz, 2H, aromatic), 7.94 (d, J = 16.1 Hz, 1H, 
CH), 6.68 (d, J = 16.1 Hz, 1H, CH), 4.30 (dd, J = 
13.8, 6.8 Hz, 2H, OCH2), 1.36 (t, J = 6.9 Hz, 3H, 
CH3); ESI-MS: m/z [M+H]
+ 316. 
Methyl (E)-3-(2-hydroxy-3,5-
dinitrophenyl)acrylate, 3w: Colourless solid. 
m.p.148-150°C. 1H NMR (400 MHz, CDCl3): δ 11.72 
(s, 1H, OH), 9.07 (d, J = 2.7 Hz, 1H, aromatic), 8.68 
(d, J = 2.7 Hz, 1H, aromatic), 7.98 (d, J = 16.2 Hz, 
1H, CH), 6.76 (d, J = 16.2 Hz, 1H, CH), 3.86 (s, 3H, 
OCH3); 
13C NMR (101 MHz, CDCl3): δ 166.22, 
157.29, 139.75, 135.03, 133.27, 129.51, 127.64, 
124.01, 121.90, 52.20; ESI-MS: m/z [M+H]+ 269. 
Ethyl (E)-3-(2-hydroxy-3,5-
dinitrophenyl)acrylate, 3x: Colourless solid. 
m.p.143-147°C. 1H NMR (400 MHz, CDCl3): δ 11.72 
(s, 1H, OH), 9.07 (d, J = 2.7 Hz, 1H, aromatic), 8.68 
(d, J = 2.7 Hz, 1H, aromatic), 7.97 (d, J = 16.2 Hz, 
1H, CH), 6.76 (d, J = 16.2 Hz, 1H, CH), 4.32 (q, J = 
7.1 Hz, 2H, OCH2), 1.37 (t, J = 7.1 Hz, 3H, OCH3); 
13C NMR (101 MHz, CDCl3): δ 165.76, 157.27, 
139.74, 134.72, 133.25, 129.45, 127.74, 124.48, 
121.82, 61.16, 14.22; ESI-MS: m/z [M+H]+ 283. 
 
DPPH free radical scavenging assay 
Assay for the scavenging of stable free radical 1,1-
diphenyl-2-picrylhydrazyl (DPPH) was done. Briefly, 
in a 96-well micro plate, 25 µL of test sample 
dissolved in DMSO (1 mg/mL), 100 µL of 0.1 M tris-
HCl buffer (pH 7.4) and 125 µL of 0.5 mM DPPH 
solution dissolved in absolute ethyl alcohol were 
added. The reaction mixture was shaken well and 
incubated in dark for 30 min and read at 517 nm 
spectrophotometrically (Spectra Max plus 384, 
Molecular Devices Corporation, Sunnyvale, CA, 
USA). Percentage of DPPH scavenging was 
calculated as (1-B/ A) × 100 where A represents 
absorbance of control without test samples and B 
represents absorbance in presence of test samples. 
 
ABTS.+ free radical scavenging assay 
Scavenging of the ABTS.+ [2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid)] cation was 
performed as described by Walker and Everette9. 
Briefly, 100 mL stock solution of ABTS.+ (0.5 mM) 
was prepared by addition of 1 mL potassium 
persulfate (6.89 mM PBS, pH 8.0). The mixture was 
stored in the dark for 16 h. Test compounds were 
dissolved in DMSO (5mg/mL). Primary screening 
was done by mixing 10 μL of test compounds in 100 
μL of methanol followed by 190 μL of ABTS.+ in a 
96-well microplate. Absorbance of decolorized 
ABTS.+ was measured at 734 nm after 15 min 
incubation in the dark on a BioTeksynergy4 multi-
mode microplate reader. For each test sample a 
separate blank sample (devoid of ABTS.+) was used 
for background subtraction. The percentage of 
ABTS.+ scavenging was calculated applying 
following formula; % ABTS.+ scavenging = 
[(Absorbance control-Absorbance test)/Absorbance 
control × 100]. Various serial dilutions of active 
compounds were prepared and tested for 
determination of SC50 values. Suitable regression 
analysis was applied for calculation of SC50. 
 
α-Glucosidase inhibitory assay 
α-Glucosidase inhibitory activity was determined 
as per our earlier reported method. Rat intestinal 
acetone powder in normal saline (100:1; w/v) was 
sonicated properly and the supernatant was used as a 
source of crude intestinal α-glucosidase after 
centrifugation. In brief, 10 μL of test samples (5 
mg/mL DMSO solution) were reconstituted in 100 µL 
of 100 mM-phosphate buffer (pH 6.8) in 96-well 
microplate and incubated with 50 µL of crude 
intestinal α-glucosidase for 5 min before 50 µL 
substrate (5 mM, p-nitrophenyl-α-D-glucopyranoside 
prepared in same buffer) was added. Release of p-
nitrophenol was measured after 15 min incubation at 




405 nm spectrophotometrically (SpectraMaxplus384), 
Molecular Devices Corporation, Sunnyvale, CA, 
USA) 5 min after incubation with substrate. 
Individual blanks for test samples were prepared to 
correct background absorbance where substrate was 
replaced with 50 µL of buffer. Control sample 
contained 10 µL DMSO in place of test samples. 
Percentage of enzyme inhibition was calculated as (1-
B/A) × 100 where [A] represents absorbance of 
control without test samples, and [B] represents 
absorbance in the presence of test samples. 
 
Conclusions 
In conclusion, α,β-unsaturated esters 3a-x have 
been prepared by the reaction of salicylaldehydes 1a-e 
with Wittig reagents 2a-b in dry DCM at RT. The 
compounds were evaluated for their free-radical 
scavenging and α-glucosidase inhibitory activities. 
Compounds 3c and 3d identified as DPPH free radical 
scavengers. Twenty compounds 3a-r and 3u-v  
have shown promising ABTS.+ free radical 
scavenging activity. Compound 3r identified as potent 
α-glucosidase inhibitor and compounds 3g and 3p 
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